Recent Material Events - Repros Therapeutics (RPRX)

Filing Date	Description
2008-10-03	In connection with the closing of the Repros Therapeutics Inc.’s (the “Company’s”) previously announced direct registered offering, on October 2, 2008, the Company and Efficacy Capital, LTD (“Efficacy”) entered into that ...
2008-09-29	On September 29, 2008, the Company entered into common stock purchase agreements with Efficacy Capital, LTD (“Efficacy”), two investors affiliated with Vermillion Asset Management LLC (each, a “Vermillion Affiliate,” and collectiv ...
2008-08-21	Repros Therapeutics Inc. (the “Company”) today released the evaluation of the microscopic assessment of tissues from a six-month mouse study conducted to satisfy a portion of the FDA mandated two-species trials to demonstrate the lack of ca ...
2008-08-18	Repros Therapeutics Inc. (the “Company”) announced today that its management will hold a conference call to provide an update on the Company’s current status and to answer questions at 12:00 noon Central Time on August 21, 2008. Domest ...
2008-07-28	On July 28, 2008, Repros Therapeutics Inc. (the “Company”) and Efficacy Capital, LTD (“Efficacy”) entered into an amendment (the “Amendment”) to that certain Standstill Agreement (the “Standstill Agreement”) da ...
2008-07-21	On July 16, 2008, Repros Therapeutics Inc. (the “Company”) released results from its completed extension safety study of Proellex ® in the chronic treatment of the symptoms associated with uterine fibroids. ...
2008-07-15	Repros Therapeutics Inc. (the “Company”) announced today that it will host an analyst meeting for the financial community beginning at 10:00 a.m. Eastern Time on Thursday, July 24, 2008 in New York City. The event, which is by invitation on ...
2008-06-10	On June 8, 2008, the Compensation and Option Committee of the Board of Directors of Repros Therapeutics Inc. (the “Committee”) approved a base salary increase retroactive to June 1, 2008 of 10% for the following named executive officers: An ...
2008-05-29	The Company today released results from its one-year extension safety study of Proellex in the chronic treatment of the symptoms associated with uterine fibroids. ...
2008-05-28	The information in this Current Report is being furnished pursuant to Item 7.01 of Form 8-K and, according to general instruction B.2. thereunder, the information in this Current Report shall not be deemed “filed” for the purposes of Sectio ...